BioMarin Trial Halt Raises Another Safety Flag On AAV Gene Therapy

US FDA Safety Probe Is Ongoing

Animal studies have shown that AAV viral vectors can integrate into animal cell DNA – but whether that causes cancer, or could happen in humans, remains uncertain.

Brisbane, CA, USA - Mar 1, 2020: The BioMarin logo seen at American biotechnology company BioMarin Pharmaceutical Inc.'s office in Brisbane, California.
BioMarin is the latest company to be hit by AAV gene therapy safety doubts, as the FDA takes a cautious approach to the burgeoning field.

More from Alimentary/Metabolic

More from Therapy Areas